In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to finish the week on a very positive note. The benchmark index is currently up a sizeable 1.6% to 5,971.5 points.
Four shares that have failed to follow the market higher today are listed below. Here’s why they are dropping lower:
The Atlas Arteria Group (ASX: ALX) share price is down almost 3% to $6.11. This morning the toll road operator’s shares traded ex-dividend for its 11 cents per share interim dividend. In addition to this, rising coronavirus cases in Europe appear to be weighing on its shares. Atlas Arteria has a collection of toll roads in France which could experience subdued traffic volumes in the near term if Europe goes back into lockdown.
The Cochlear Limited (ASX: COH) share price is down almost 1% to $200.65. Earlier this week UBS reaffirmed its sell rating and $175.00 price target on this hearing solutions company’s shares. Its analysts believe that the market is expecting too much from Cochlear in respect to sales growth in the coming years.
The Telix Pharmaceuticals Ltd (ASX: TLX) share price has fallen 1.5% to $1.75. This decline appears to be down to profit taking after some strong gains in recent months by the biopharmaceutical company’s shares. For example, prior to today, Telix’s shares were up a massive 115% over the last six months.
The Treasury Wine Estates Ltd (ASX: TWE) share price has dropped almost 1% to $9.00. Investors have been selling the wine company’s shares despite it being subject to a positive broker note out of Credit Suisse yesterday. The broker has upgraded Treasury Wine’s shares to an outperform rating with a $12.30 price target. This price target implies potential upside of almost 37% for its shares over the next 12 months. Clearly some investors aren’t as bullish on its prospects.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...
Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
Returns as of 6th October 2020
James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended Treasury Wine Estates Limited. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Why the Rhythm Biosciences (ASX:RHY) share price rocketed 28% to a record high – December 4, 2020 4:51pm
- Here’s why the Home Consortium (ASX:HMC) share price is in a trading halt – December 4, 2020 3:35pm
- Brokers name 3 ASX shares to buy right now – December 4, 2020 2:48pm